EUREGHA joins pan-European effort to improve early cancer detection in Lynch Syndrome through PREDI-LYNCH project
EUREGHA is proud to be part of PREDI-LYNCH – a newly launched, ambitious project that aims to revolutionise early detection of hereditary cancers associated with Lynch Syndrome (LS). Funded under the Horizon Europe Mission on Cancer, the project officially kicked off on 1 May 2025 and will run for six years.
Coordinated by Oslo University Hospital, PREDI-LYNCH brings together 28 partners from 16 countries. The project will focus on developing and validating non-invasive liquid biopsy-based tests for the early detection of colorectal, endometrial and urothelial cancers, the three most common types affecting LS patients.
A European collaboration to transform hereditary cancer care
Despite the growing recognition of Lynch Syndrome across Europe, effective and tolerable early detection strategies remain limited. PREDI-LYNCH directly addresses this gap by integrating multi-omics technologies, AI-powered analysis, and a unique biobank for LS patients. The project is expected to pave the way for personalised and scalable screening approaches across different healthcare systems in the EU.
EUREGHA’s role: bridging research and policy
As a partner in the project, EUREGHA will contribute by:
-
Engaging with regional and local health authorities across Europe,
-
Supporting policy uptake and promoting the integration of innovative solutions in regional cancer strategies,
-
Ensuring that project results reach relevant stakeholders to support future implementation at health system level.
Our involvement ensures that the needs of regions and patients are considered from the earliest stages of innovation – and that successful approaches are shared across borders.
